U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Xeroderma pigmentosum(XP)

MedGen UID:
21943
Concept ID:
C0043346
Congenital Abnormality
Synonyms: Xeroderma pigmentosa; XP
SNOMED CT: XP - Xeroderma pigmentosum (44600005); Xeroderma pigmentosum (44600005); Xeroderma of Kaposi (44600005); Melanosis lenticularis progressiva (44600005); Kaposi dermatosis (44600005); Pigmented epitheliomatosis (44600005); Atrophoderma pigmentosum (44600005); Angioma pigmentosum atrophicum (44600005)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
 
Gene (location): ERCC1 (19q13.32)
Related genes: XPC, XPA, POLH, ERCC5, ERCC4, ERCC3, ERCC2, DDB2
 
Monarch Initiative: MONDO:0019600
Orphanet: ORPHA910

Disease characteristics

Excerpted from the GeneReview: Xeroderma Pigmentosum
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years). [from GeneReviews]
Authors:
Kenneth H Kraemer  |  John J DiGiovanna  |  Deborah Tamura   view full author information

Additional description

From MedlinePlus Genetics
Xeroderma pigmentosum, commonly known as XP, is an inherited condition characterized by an extreme sensitivity to ultraviolet radiation (UVR), which is present in sunlight and may also be found in some types of artificial lighting. This condition mostly affects the eyes and areas of skin exposed to the sun. Xeroderma pigmentosum is associated with an increased risk of UVR-induced cancers. People with this condition often experience premature aging. Some affected individuals also have problems involving the nervous system.

The signs of xeroderma pigmentosum usually appear in infancy or early childhood. About half of affected children develop a severe sunburn after spending just a few minutes in the sun. The sunburn causes redness and blistering that can last for weeks. However, some children with xeroderma pigmentosum can tan normally. 

By age 2, almost all children with xeroderma pigmentosum develop freckling of the skin in sun-exposed areas (such as the face, arms, and lips); this type of freckling rarely occurs in young children without the disorder. In affected individuals, exposure to sunlight often causes dry skin (xeroderma) and changes in skin coloring (pigmentation). This combination of features gives the condition its name.

People with xeroderma pigmentosum are 10,000 times more likely to develop non-melanoma skin cancer and up to 2,000 times more likely to  develop melanoma skin cancer compared to individuals without this condition. The types of skin cancer that can develop include basal cell carcinoma, squamous cell carcinoma, and melanoma. Most commonly, the first skin cancer appears in affected individuals before age 10. 

Without protection from the sun and other sources of UVR, most people with xeroderma pigmentosum develop multiple skin cancers during their lifetime. These cancers occur most often on  portions of the body that are exposed to the sun, including the face, the lips, the eyelids, the surface of the eyes, the scalp, and the tip of the tongue. Studies suggest that people with xeroderma pigmentosum may also have an increased risk of some internal cancers, including brain tumors, thyroid cancer, and blood cancers. Additionally, affected individuals who smoke cigarettes have a significantly increased risk of lung cancer.

The eyes of people with xeroderma pigmentosum may be painfully sensitive to UVR (photophobia). If the eyes are not protected from UVR, they may become bloodshot and irritated, and the clear front covering of the eyes (the cornea) may become cloudy. In some people, the eyelashes fall out and the eyelids may be thin and turn abnormally inward or outward. In addition to an increased risk of cancer on the surface of the eye, xeroderma pigmentosum is associated with noncancerous growths on the eye. Many of these eye abnormalities can impair vision.

About 30 percent of people with xeroderma pigmentosum develop progressive neurological abnormalities in addition to problems involving the skin and eyes. These abnormalities can include hearing loss, poor coordination, difficulty walking, movement problems, loss of intellectual function, difficulty swallowing and talking, and seizures. When these neurological problems occur, they tend to worsen with time.

Researchers have identified at least eight genetic forms of xeroderma pigmentosum: complementation group A (XP-A) through complementation group G (XP-G), plus a variant type (XP-V). The types are distinguished by their genetic cause. All of the types increase the risk of skin cancer, although some are more likely than others to be associated with neurological abnormalities.

Individuals with xeroderma pigmentosum may experience early menopause.  https://medlineplus.gov/genetics/condition/xeroderma-pigmentosum

Professional guidelines

PubMed

Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori C; Xeroderma pigmentosum clinical practice guidelines revision committee
J Dermatol 2017 Oct;44(10):1087-1096. Epub 2017 Aug 3 doi: 10.1111/1346-8138.13907. PMID: 28771907
Fassihi H
Br J Dermatol 2015 Apr;172(4):859-60. doi: 10.1111/bjd.13577. PMID: 25827741
Schubert S, Lehmann J, Kalfon L, Slor H, Falik-Zaccai TC, Emmert S
Eur J Hum Genet 2014 Jul;22(7) Epub 2013 Oct 9 doi: 10.1038/ejhg.2013.233. PMID: 24105368Free PMC Article

Suggested Reading

Recent clinical studies

Etiology

Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Houten BV, Kuper J, Kisker C
DNA Repair (Amst) 2016 Aug;44:136-142. Epub 2016 May 16 doi: 10.1016/j.dnarep.2016.05.019. PMID: 27262611
Sugitani N, Sivley RM, Perry KE, Capra JA, Chazin WJ
DNA Repair (Amst) 2016 Aug;44:123-135. Epub 2016 May 20 doi: 10.1016/j.dnarep.2016.05.018. PMID: 27247238Free PMC Article
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article
Webb S
BMJ 2008 Feb 23;336(7641):444-6. doi: 10.1136/bmj.39485.698356.AD. PMID: 18292171Free PMC Article

Diagnosis

Dev N, Aggarwal P
Indian J Med Res 2020 Nov;152(Suppl 1):S74-S75. doi: 10.4103/ijmr.IJMR_2097_19. PMID: 35345132Free PMC Article
Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Webb S
BMJ 2008 Feb 23;336(7641):444-6. doi: 10.1136/bmj.39485.698356.AD. PMID: 18292171Free PMC Article
Jung EG
Int J Dermatol 1986 Dec;25(10):629-33. doi: 10.1111/j.1365-4362.1986.tb04522.x. PMID: 3542861
Der Kaloustian VM, Kurban AK
Br J Dermatol 1973 May;88(5):513-5. doi: 10.1111/j.1365-2133.1973.tb15461.x. PMID: 4577062

Therapy

Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Shah P, He YY
Photochem Photobiol 2015 Mar-Apr;91(2):254-64. Epub 2015 Jan 14 doi: 10.1111/php.12406. PMID: 25534312Free PMC Article
Jung EG
Int J Dermatol 1986 Dec;25(10):629-33. doi: 10.1111/j.1365-4362.1986.tb04522.x. PMID: 3542861
Kraemer KH, Slor H
Clin Dermatol 1985 Jan-Mar;3(1):33-69. doi: 10.1016/0738-081x(85)90096-3. PMID: 3833325
Ramsay CA
Pediatr Clin North Am 1983 Aug;30(4):687-99. doi: 10.1016/s0031-3955(16)34434-0. PMID: 6351001

Prognosis

Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Black JO
Head Neck Pathol 2016 Jun;10(2):139-44. Epub 2016 Mar 14 doi: 10.1007/s12105-016-0707-8. PMID: 26975629Free PMC Article
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article
Jen M, Murphy M, Grant-Kels JM
Clin Dermatol 2009 Nov-Dec;27(6):529-36. doi: 10.1016/j.clindermatol.2008.09.011. PMID: 19880040
Kulkarni ML, Rani RS
Indian Pediatr 1996 May;33(5):394-8. PMID: 8979588

Clinical prediction guides

Feltes BC
Mutat Res Rev Mutat Res 2022 Jan-Jun;789:108416. Epub 2022 Mar 29 doi: 10.1016/j.mrrev.2022.108416. PMID: 35690419
Khan S, Cvammen W, Anabtawi N, Choi JH, Kemp MG
DNA Repair (Amst) 2022 Jan;109:103260. Epub 2021 Dec 2 doi: 10.1016/j.dnarep.2021.103260. PMID: 34883264Free PMC Article
Quintero-Ruiz N, Corradi C, Moreno NC, de Souza TA, Pereira Castro L, Rocha CRR, Menck CFM
Photochem Photobiol 2022 May;98(3):713-731. Epub 2021 Sep 30 doi: 10.1111/php.13516. PMID: 34516658
Kap EJ, Popanda O, Chang-Claude J
Pharmacogenomics 2016 May;17(7):755-94. Epub 2016 May 16 doi: 10.2217/pgs-2015-0017. PMID: 27183147
Daya-Grosjean L
Adv Exp Med Biol 2008;637:19-27. doi: 10.1007/978-0-387-09599-8_3. PMID: 19181107

Recent systematic reviews

Brambullo T, Colonna MR, Vindigni V, Piaserico S, Masciopinto G, Galeano M, Costa AL, Bassetto F
Biomed Res Int 2022;2022:8549532. Epub 2022 Jul 18 doi: 10.1155/2022/8549532. PMID: 35898688Free PMC Article
Tavares CB, Gomes-Braga FDCSA, Sousa EB, Brito JNPO, Melo MA, Campelo V, Neto FM, de Araújo RML, Kessler IM, Sousa Júnior LM, Filho LCC, Aguiar YQ, Lopes Costa PV, da Silva BB
Cancer Invest 2020 Mar;38(3):169-183. Epub 2020 Mar 2 doi: 10.1080/07357907.2020.1719502. PMID: 31957502
George C, Yako YY, Okpechi IG, Matsha TE, Kaze Folefack FJ, Kengne AP
BMC Med Genet 2018 Oct 19;19(1):187. doi: 10.1186/s12881-018-0702-x. PMID: 30340464Free PMC Article
Ding D, Zhang Y, Yu H, Guo Y, Jiang L, He X, Ma W, Zheng W
Int J Cancer 2012 Jul 15;131(2):488-96. Epub 2011 Oct 20 doi: 10.1002/ijc.26391. PMID: 21866550
Wang F, Chang D, Hu FL, Sui H, Han B, Li DD, Zhao YS
Cancer Epidemiol Biomarkers Prev 2008 Mar;17(3):507-17. doi: 10.1158/1055-9965.EPI-07-2507. PMID: 18349268

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...